U.S. Markets open in 1 hr 54 mins

Aeterna Zentaris Inc. (AEZS)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
2.30-0.57 (-19.86%)
At close: 4:00PM EDT

2.40 0.10 (4.35%)
Pre-Market: 7:22AM EDT

People also watch
KERXCYCCAVEOGALEOPXA
  • Watch for $3.50 this week as it carries momentum from last week's strong news. FDA approval makes this a $10.00 stock at least.
  • new CEO is going to sell the company and previous CEO was against it.
  • this will end in green today
  • Fake pump and dump. Hedge funds play toy.
  • Don't listen to the naysayers. Everything from Microsoft to Google took a hit. It'll go back up.
  • $2.25 close ?
  • A REAL LIFETIME OPPRTUNITY HERE .....
    KTOV = Mcap $16 Mil /Cash $17 Mil / ULTRA Low float O/S 10.6 M / NDA submission for potential Blockbuster this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys

    Kitov Pharma (KTOV)

    Market Cap: $17 M
    Cash $17 M
    Price: $1.50

    Shares Out: 10.6 Million

    Kitov Pharmaceuticals Initiates NDA Filing for KIT-302 as a Treatment for Osteoarthritis and Hypertension
    https://baystreet.ca/articles/research_reports/lifesci/Kitov062717.pdf

    Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.

    KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

    Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

    Marketing potential Pipeline candidates address large, multi-billion dollar markets

    “KIT-302 has the potential to address the multi-billion dollar market for the treatment of osteoarthritis pain and hypertension with one drug that reduces patients’ risk of suffering a heart attack or stroke, while also reducing cost for payers. There is currently no single medication on the market that treats both osteoarthritis pain and hypertension and thus, KIT-302 will be the only NSAID indicated both to treat pain and to reduce the risk of heart attack, stroke and death.”

    Pain medications for osteoarthritis account for billions of dollars in annual sales globally. Most pain medications for osteoarthritis, including celecoxib which had global sales of $2.7 billion in 2014, are non-steroidal anti-inflammatory drugs (NSAIDs) which have the side effect of elevating blood pressure, and increasing the risk of heart attacks, strokes and death. Of the 27 million Americans who live with osteoarthritis, 13.5 million also suffer from hypertension, which also increases the risk of heart attack, stroke, and death.

  • I'm holding on. It's only Monday. Fear got the best of the bears. Bulls will bring it back later this week.
  • Just bought at 2.49 :) its going up
  • pump job so ceo and bigs could sell.
  • How they will increase share holder value? it was under reverse split from 5 years...your one share $8000 became $2 in past 5 years.
  • Wow look at all the negative ideas. Just a pullback chill
  • Down 20% more tomorrow GUARANTEED!
  • If it breaks 2.41/sh stock will free fall....
  • Ugh I made the rookie mistake of investing based on the hype. It'll probably crash on Monday, good thing I didn't invest a lot into this. Always do your due diligence folks!
  • Bought Friday 25,000 shares at 3.31 expecting at least 40% of gains soon.
    Imagenba-80s-90sgifs
  • Appoint Micheal Ward as CEO. His only job is to sale the company, the sales tag: 15/share
  • Bought 21,400 shares of this in the premarket yesterday at $1.51. Still holding onto all the shares and extremely happy. Already up almost 30 grand
  • ACRX up 16% today... 220% to go based on HC Wainwright's Price Target... AEZS need some color from the NEW CEO... Keep In Mind, in 2015 AEZS, CEO DODD, did a 100:1 Reverse Split...
  • No sale or deal = .78/sh.There is little to no institutional support so the stock will free fall. Sell AEZS asap because the market is about to crash. Buy TZA...... Good luck